CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Chinook Therapeutics Announces News COO and CSO

Life Sciences Review Life Sciences Review | Friday, June 18, 2021
Tweet

Chinook Therapeutics announces Tom Frohlich as the chief operating officer and Andrew King as the chief scientific officer.


FREMONT, CA: Chinook Therapeutics, Inc., a clinical-stage biopharmaceutical firm dedicated to the discovery, development, and commercialization of precision medicines for kidney diseases, has announced that Tom Frohlich, chief business officer, has been raised to the position of chief operating officer (COO), and Andrew King, D.V.M, Ph.D., head of renal discovery and translational medicine, has been introduced as the chief scientific officer (CSO) of Chinook.


“We are thrilled to announce these extremely well-deserved promotions for both Tom and Andrew to recognize the important roles they are playing in building Chinook into a leading kidney disease company,” said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. “Tom is a seasoned commercial and business development executive who co-founded Chinook, led business negotiations with AbbVie for our license to atrasentan and our merger with Aduro, and has assumed broad operational responsibilities at the company. Andrew is a highly-respected expert in kidney disease biology who was instrumental in bringing both atrasentan and BION-1301 into our pipeline and leads a top-notch discovery, research and translational medicine team at Chinook focused on advancing our pipeline of novel, precision medicines for kidney disease.”


Tom will be in charge of business development, CMC, quality, new product planning, programme management, and program team leadership for Chinook in his role as COO. Tom co-founded Chinook and became its chief business officer in January 2019. Before joining Chinook, he worked at Versant Ventures as an entrepreneur-in-residence.


Andrew will be in charge of the discovery research, non-clinical development, and translational medicine teams as CSO. He became the head of renal discovery and translational medicine at Chinook in May 2019. Andrew was a senior director of discovery and translational biology at Ardelyx before joining Chinook, where he and his team were instrumental in delivering small molecule candidates for the medication of cardio-renal diseases and elucidating the novel molecular mechanism of action of tenapanor, which is currently undergoing FDA NDA review for the treatment of hyperphosphatemia in dialysis patients.


Weekly Brief

loading
Top 10 Preeminent Cros – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/chinook-therapeutics-announces-news-coo-and-cso-nwid-403.html